Polyclonal Antibody to Chemokine C-C-Motif Receptor 7 (CCR7)
| Code | Size | Price |
|---|
| PAB647Mu02-20ul | 20ul | £86.00 |
Quantity:
| PAB647Mu02-100ul | 100ul | £158.00 |
Quantity:
| PAB647Mu02-200ul | 200ul | £214.00 |
Quantity:
| PAB647Mu02-1ml | 1ml | £488.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Mouse
Applications:
- Immunocytochemistry (ICC)
- Immunohistochemistry (IHC)
- Immunoprecipitation (IP)
- Western Blot (WB)
Further Information
Alternative Names:
CD197; CCR7; BLR2; CDw197; CMKBR7; EBI1; Epstein-Barr Virus Induced Protein 1; EBV-induced G-protein coupled receptor 1; MIP-3 beta receptor
Buffer Formulation:
PBS, pH7.4, containing 0.02% NaN3, 50% glycerol.
Item Name:
Chemokine C-C-Motif Receptor 7
Source:
Polyclonal antibody preparation
Usage:
Western blotting: 0.5-2ug/mL;1:180-740
Immunohistochemistry: 5-20ug/mL;1:18-74
Immunocytochemistry: 5-20ug/mL;1:18-74
Optimal working dilutions must be determined by end user.
Immunohistochemistry: 5-20ug/mL;1:18-74
Immunocytochemistry: 5-20ug/mL;1:18-74
Optimal working dilutions must be determined by end user.
Related Products
| Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant Chemokine C-C-Motif Receptor 7 (CCR7) | RPB647Mu01 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||